ANGLE’s Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.”
Andrew Newland
Chief Executive

An introduction to the Parsortix system

Video interview on Parsortix FDA submission View Here